BioCardia is developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases.Their mission is to improve the lives of patients with cardiovascular and pulmonary diseases through the development of meaningful therapeutics
BioCardia is FDA designated "Breakthrough" investigational CardiAMP™ Cell Therapy, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications - ischemic heart failure (BCDA-01) and chronic myocardial ischemia (BCDA-02).
The following is the list of scholars from The University of Texas MD Anderson Cancer Center who currently serve as editors for one or more SciTechnol journals.
- Ian K McNiece
- Patrick M Dougherty, PhD
- Vickie R Shannon, MD
- C. Cameron Yin, MD, PhD
- Ken H Young, PhD
- Ken H Young
- Ken H. Young, MD, PhD
- Kai Cao
The following is the list of scholars from The University of Texas MD Anderson Cancer Center who published one or more articles in SciTechnol journals.
The following is the list of articles by scholars from The University of Texas MD Anderson Cancer Center that are published in SciTechnol journals.
Drug Screening: The Critical Step in the Drug Discovery ProcessCommentary: J Regen Med
Gene Therapy for Mitochondrial Diseases: A Promising Approach to Restoring Mitochondrial FunctionMini Review: J Regen Med
Neuroregeneration: Restoring Function through Repair of Damaged Neurons in the CNSRapid Communication: J Regen Med
Understanding the Intricate Mechanisms of Axogenesis: A Crucial Process for Nervous System Development and FunctionPerspective: J Regen Med
Clinical Significance of Image Analysis of Biomaterial-Tissue InteractionsOpinion Article: J Regen Med